The value of the pipeline is not in their legacy program Trimesta. C-Diff and IBS drug are their main goals now with Pertussis a distant third on the pipeline. If Trimesta was their focus then they wouldn't be doing a partnership and would have it featured in their new presentation. I am fully aware of this and I still believe the value driver is SYN 004 by any measure. Just wanted to lay it out for you. Legacy Drug Trimesta- Partnership with some royalty potential (they really will want more cash upfront if possible), Pertussis- Non-dilutive financing? Since they are partnered with Intrexon likely something Kirk will help set up with a University, MD Anderson, or some grant (private or government). SYN 004 (C-Diff) and SYN 010 (IBS) they plan to try to take through phase III. I like their future but they do need cash to make the future happen. Not impressed with the dilution (hence their announcement to look for specifically non-dilutive financing) to date but I am strong believer in C-Diff drug potential. Anything for Trimesta would be nice.
I believe people are getting confused on what is being long term vs short term. Just because someone is not bullish short term does not mean they are not bullish long term. I happen to enjoy long term capital gains so I don't really play the game back and forth but for everyone debating so furiously on this board I thought I should point out the difference. Maybe everyone is right.